

Comparative *in silico* analyses of proteins involved in serum resistance as promising vaccine candidates against *Acinetobacter baumannii*

Soltani Shirazi A¹, Azizi O², Bolourchi N¹, Aghamohammad Sh¹, Badmasti F^{1*}

¹Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.

²Department of Basic Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.

ABSTRACT

Introduction: *Acinetobacter baumannii* as a Gram-negative coccobacillus has become a major cause of hospital-acquired infections. The virulence factors involved in serum resistance are important targets in the development of an effective vaccine against this pathogen. Our aim in this project was *in silico* analyses of *A. baumannii* proteins involved in serum resistance which could potentially be used as efficient vaccines. **Methods:** Based on computational procedures, we evaluated all *A. baumannii* proteins involved in serum resistance, namely AbOmpA, PKF, PLD, PBP 7/8, CipA and Tuf SurA1, as vaccine candidates. Subcellular localization, sequence conservation, domain prediction and 3D modelings were analyzed by online tools. Moreover, the prevalence of serum resistance factors in 5 strains of *A. baumannii* was characterized. The MHC-binding sites of class I and II were detected. Linear and conformational B cell epitopes were analyzed by 2 prediction servers. **Results:** The MetaLocGramN server showed that AbOmpA, PKF, PBP7/8, phospholipase D, CipA, Tuf and SurA1 were outer membrane protein (56.32%), extracellular protein (58.74%), extracellular protein (52.59%), cytoplasmic protein (45.08%), extracellular protein (53.8%), Cytoplasmic protein (96.36%) and extracellular protein (58.23%), respectively. The OMD of AbOmpA, PKF, PBP7/8 and phospholipase D, CipA, Tuf and SurA1 were 0.060, 0.076, 0.08, 0.101, 0.09, 0.06 and 0.103, respectively. The numbers of immunogenic linear and conformational epitopes with high score ($P \geq 0.6$), extracted from beta-barrel of AbOmpA were 6 and 4; whereas these values for PKF were 10 and 4, respectively. **Conclusion:** The *in silico* analyses and reverse vaccinology criteria showed that AbOmpA and PKF had better attributes as vaccine targets and they could be considered as promising vaccine candidates against *A. baumannii*.

KEYWORDS: *Acinetobacter baumannii*, *in silico* analysis, serum resistance factors.

INTRODUCTION

Acinetobacter baumannii is a Gram-negative coccobacillus and a major causative agent of nosocomial infections. Infections caused by this bacterium could be resulted in bacteremia, urinary tract infections and surgical site infections, especially in the intensive care units [1]. Resistance genes could be easily transferred to this organism which can lead to therapeutic failures with respect to the infection [2]. In recent years, outbreaks of multidrug-resistant (MDR) strains of this bacterium in hospitals have caused worldwide health crises [1]. Therefore, new approaches based on immunological strategies such as active and passive immunizations have been developed to prevent or treat infections caused by the MDR strains. Sepsis caused by *A. baumannii* could cause high mortality [3]. The virulence factors involved in serum resistance are important targets in development of an effective vaccine. OmpA of *A. baumannii* (AbOmpA) is one of the most important virulence factors which is involved in adherence and

biofilm formation by the bacterium [4]. Furthermore, new factors such as serine protease PKF, involved in serum resistance have been recently characterized. PKF is associated with resistance to complement system and suppresses the biofilm formation [5]. A study based on transposon mutant library has shown that disruption of *A. baumannii* phospholipase D (PLD) could result in reduction of serum resistance [6]. Moreover, it has been shown that a transposon mutant in an *A. baumannii* gene for penicillin binding protein 7/8 (PBP 7/8) could lead to reduction in the virulence in a rat model of pneumonia as well as reduced serum resistance capability [7]. Meanwhile, novel serum resistance factors, including CipA as a plasminogen binding and complement inhibitory protein, elongation factor Tuf and surface antigen protein 1 (SurA1), have been characterized [8-10].

Ideally, a vaccine candidate protein should play critical roles in pathogenesis of a bacterium and be conserved amongst all the related strains. Moreover, it should be exposed to extracellular spaces to be easily presented to the immune system. Having one or more immunogenic epitopes that elicit a protective immune response in humans or animal models is another important feature for a protein to be an efficient vaccine candidate [11]. In

*Corresponding Author: Farzad Badmasti, Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
Email: fbadmasti2008@gmail.com
Tel/Fax: (+98) 2166405535

this regard, here we used bioinformatics tools to assess *A. baumannii* proteins involved in serum resistance in order to define potentially effective vaccine targets for this pathogen.

MATERIALS and METHODS

Comparative analyses

All serum resistance proteins were retrieved in FASTA format from Uniprot database <<http://www.uniprot.org/>> [12]. The subcellular localizations of the proteins were detected by MetaLocGramN <<http://genesilico.pl/MetaLocGramN/>>; a meta-server for subcellular localization and prediction of Gram-negative proteins (i.e. proteins which are extracted from Gram-negative bacteria) [13]. All domains of the proteins were identified in NCBI CD-search <<http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi>> domain prediction tool [14]. VICMpred was applied to predict the role of the protein in bacteria <<http://www.imtech.res.in/raghava/vicmpred/>>; which is a Support Vector Machine (SVM)-based method using amino acid patterns and composition to predict functional proteins of Gram-negative bacteria [15]. The overall antigenicity of proteins was evaluated in VaxiJen <<http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html>> [16]. The adhesion probability, trans-membrane helices and similarity to eukaryotic proteins were checked in Vaxitop server <<http://www.violinet.org/vaxign/vaxitop/index.php>> [17].

Prevalence of serum resistance factors in *A. baumannii* strains

The prevalence of serum resistance factors in 5 strains of *A. baumannii* was characterized by bacterial genome BLAST tool in ENSEMBL server <<http://bacteria.ensembl.org/Multi/Tools/Blast>> [18]. *A. baumannii* AB0057 (ST-1, international clone -I), ACICU (ST-2, international clone-II), ATCC 17978 (Non-international clone), MDR-TJ (as a multi-drug resistant), D1279779 (agent of community acquired infection) and SDF (non-pathogenic) strains were considered in this analysis. These 5 strains covered the basic genome structure of *A. baumannii*, as previously reported [37]. The whole genomes of these strains have been sequenced previously and deposited in genome database.

Sequence conservation analysis

The ConSurf <<http://consurf.tau.ac.il/>>, a server for estimating the evolutionary conservation of amino/nucleic acid positions in a protein/DNA/RNA molecule, based on the phylogenetic relations between homologous sequences [19], was used for identification of the conserved regions in the mentioned proteins. Moreover, we computed the overall mean distance (OMD) of 100 non-redundant protein sequences of each serum resistance factors by MEGA v6.0 software [20]. This value represents 1/conservation.

MHC binding sites prediction

The MHC binding sites of class I and II were detected by Vaxitop server <<http://www.violinet.org/vaxign/vaxitop/index.php>>. In this analysis, all human MHC alleles with any lengths of MHC binding sites were considered. The probability (*P*-value) of all binding sites was less than 0.05. The number of MHC binding sites (separately for MHC-I and MHC-II) were divided to number of whole amino acids of proteins and were reported as a ratio in Table 1.

3D molecular modeling

The secondary structures of the proteins were predicted by Jpred server <http://www.compbio.dundee.ac.uk/jpred/index_u>

.html>; a protein secondary structure prediction server [21]. Prediction of 3D molecular modeling of promising targets was done by local meta-threading server LOMETs <<http://zhanglab.ccmb.med.umich.edu/LOMETs/>>; an online web service to predict the structure of the protein which collects consensus contact predictions from multiple threading templates [22]. The best models with the highest score were selected. The predicted models were subjected to further refinement in ModRefiner server <<http://zhanglab.ccmb.med.umich.edu/ModRefiner/>> and energy minimization of predicted models were performed at high-resolution protein structure refinement web server [23].

Linear and conformational B cell epitopes prediction

Linear and conformational B cell epitopes and putative antigenic determinants were analyzed by ElliPro Prediction server [24]; a web-tool that implements Thornton's method and allows the prediction and visualization of antibody epitopes in a given protein sequence or structure together with a residue clustering algorithm <http://tools.immuneepitope.org/tools/ElliPro/iedb_input>. Based on the 3D structure of a protein antigen, ElliPro predicts linear and discontinuous antibody epitopes by homology modeling. Moreover, the conformational B cell epitope was obtained by Discotope server <<http://www.cbs.dtu.dk/services/DiscoTope/>> for comparison with ElliPro results.

RESULTS

Subcellular localization and sequence conservation.

MetaLocGramN server showed AbOmpA, PKF, PBP7/8, phospholipase D, CipA, Tuf and SurA1 were outer membrane protein (56.32%), extracellular protein (58.74%), extracellular protein (52.59%), cytoplasmic protein (45.08%), extracellular protein (53.8%), Cytoplasmic protein (96.36%) and extracellular protein (58.23%), respectively. These results are represented in Table 1. The OMD of AbOmpA, PKF, PBP7/8 and phospholipase D, CipA, Tuf and SurA1 were 0.060, 0.076, 0.08, 0.101, 0.09, 0.06 and 0.103, respectively.

Domain prediction

Domain prediction showed AbOmpA had two independent domains as follows: beta-barrel domain which could be found wildly in outer membrane proteins. This domain assumes a membrane-bound beta-barrel fold C-terminal domain AbOmpA; OmpA-like domains have been shown to non-covalently associated with peptidoglycan [25]. The secreted serine protease PKF had trypsin-like serine protease activity (Peptidase S1). Moreover, it had two PDZ domain of trypsin-like serine proteases, like DegP/HtrA, which are oligomeric proteins involved in chaperone function, apoptosis and heat-shock response [26]. This domain could play major role in substrate recognition and/or binding to C-terminal polypeptides. Penicillin binding protein 7/8 with D-alanyl-D-alanine carboxypeptidase activity had transpeptidase domain [27]. The active site of this protein has a serine residue that is conserved in all members of this family. Phospholipase D (PLD) had PLD-like domain with two repeats of catalytic domains which have been named repeat-1 and repeat-2. Phospholipid phosphodiester bonds could be hydrolyzed by PLD enzymes. This catalysis causes phosphatidic acid as well as a free polar head group. They can also catalyze trans-phosphatidylation of phospholipids to acceptor alcohols [28]. CipA protein has META domain; a small domain family found in proteins of

unknown function. Tuf is a selenocysteine-specific translation elongation factor and

SurA1 had no domain (see Table 1).

Table 1. The summarized information of comparative *in silico* analyses of proteins involved in serum resistance of *A. baumannii*

| Protein | GenBank ID | Length | Domain or function | AB00 57 | ACI CU | ATCC 17978 | MD R-TJ | D1279 779 | SDF | MetaLocGra mN ^a | Adhesion Probability | Trans- membrane helices | Similar to Eukaryotic proteins | VICM- pred ^b | Signal peptide ^c | OMD ^d | Protein Antigen icity | No. of MHC- class I and II binding sites per amino acid |
|---|-------------|--------|--|------------|-----------|---------------|------------|--------------|-----|-------------------------------|-------------------------|-------------------------------|--------------------------------------|----------------------------|--------------------------------|------------------|-----------------------------|--|
| OmpA of <i>Acinetobacter baumannii</i> (AbOmpA) | ACICU_03089 | 356 aa | Beta barrel domain, C-terminal ompA-like | + | + | + | + | + | + | OM (56.32%) | 0.476 | 1 | No | CP (3.01) | SpI (13.98) | 0.060 | 0.8457 | MHC-I:1.77 MHC-II: 0.83 |
| Serine proteases (PKF) | ACICU_02801 | 458 aa | Trypsin-like cysteine/serine peptidase domain, PDZ domain | + | + | + | + | + | + | EC (58.74%) | 0.205 | 0 | No | VF (1.35) | SpI (8.19) | 0.076 | 0.5524 | MHC-I: 1.98 MHC-II: 0.77 |
| penicillin binding protein 7/8 (Pbp7/8) | ACICU_00260 | 340 aa | Penicillin binding protein transpeptidase domain (D-alanyl-D-alanine carboxypeptidase) | + | + | + | + | + | + | EC (52.59%) | 0.495 | 0 | No | VF (1.22) | SpI (22.89) | 0.08 | 0.5417 | MHC-I: 1.92 MHC-II: 0.73 |
| phospholipase D-like proteins (PLD) | ACICU_03141 | 487 aa | PLD-like domain | + | + | + | + | + | + | CP (45.08%) | 0.266 | 1 | No | VF (0.65) | TMH (1.15) | 0.101 | 0.4507 | MHC-I: 2.17 MHC-II: 1.06 |
| CipA | ACICU_00989 | 369 aa | META domain; Small domain family found in proteins of unknown function. | + | + | + | + | + | + | EC (53.8%) | 0.651 | 0 | No | MM (1.03) | SpII (10.87) | 0.09 | 0.6646 | MHC-I: 1.87 MHC-II: 0.91 |
| Tuf | AB57_0914 | 396 aa | Selenocysteine-specific translation elongation factor | + | + | + | + | + | + | CP (96.36%) | 0.097 | 0 | Yes | IS (4.64) | CYP (0.2) | 0.06 | 0.5218 | MHC-I: 1.92 MHC-II: 0.83 |
| surface antigen protein 1 (SurA1) | AB57_1613 | 105 aa | No domain | + | + | + | + | + | - | EC (58.23%) | 0.298 | 0 | No | MM (1.50) | CYP (0.2) | 0.103 | 0.6738 | MHC-I: 1.66 MHC-II: 0.62 |

a: OM, Outer membrane; EC, Extracellular; CP, Cytoplasmic

b: CP, Cellular process; VF, Virulence factor; MM, Metabolism Molecule; IS, Information and storage

c: SpI, Signal peptide type I; TMH, N-terminal transmembrane helix; CYP, Cytoplasmic

d: OMD, overall mean distance.


Analysis of proteins based on reverse vaccinology criteria
 All proteins (except SurA1) were highly prevalent in selected strains. All proteins (except Tuf) were not similar to eukaryote proteins. All proteins (except PLD) had $P > 0.5$ overall antigenicity score. The VICMpred and signal peptide predictions showed all proteins (except CipA) were putative virulence factors and maybe directly or indirectly involved in bacterial pathogenesis (see Table 1). Taken together, our analyses showed AbOmpA and PKF are two best vaccine targets. Therefore, the following sections and other analyses were performed just on these two proteins.

3D modeling and B cell epitope predictions

A

1 MKLSRIALATMLVAAPLAAANAGVTVTPLLLGYTFQDSQ 39
 40 HNNGGKDGNLTNSPELQDDLFGAALGIELTPWLGFEEAE 78
 79 YNQVKGDVGASAGAEYKQKQINGNFYVTSDLITKNYDS 117
 118 KIKPYVLLGAGHYKYDFDGVNRGTRGTSEEGTLGNAGVG 156
 157 AFWRLNDALSLRTEARATYNADEEFWNYTALAGLNVVLG 195
 196 GHLKPAAPVVEVAPVEPTIPVAPQPQELTEDLNMELRVFF 234
 235 DTNKSNIKDQYKPEIAKVAEKLSEYPNATARIEGHTDNT 273
 274 GPRKLNERLSLARANSVKSLAVNVEYNVDASRLSTQGFAW 312
 313 DQPIADNKTKERGMNRRVFATITGSRTVVVQPGQAAA 351
 352 AAAQ 356

C



These following procedures were performed only for AbOmpA and PKF, as promising vaccine targets. Data have shown that the beta-barrel domain of AbOmpA is similar to beta-barrel domain of *Klebsiella pneumoniae* OmpA (PDB accession number is 2K0L) [29]. This domain has 4 extracellular loops. The PKF protein is homolog of DegP (PDB accession number 2ZLE). The heat-shock protein DegP is a protein quality control factor which plays different roles in regulating protease, eliminating misfolded proteins and in the biogenesis of outer-membrane proteins in *Escherichia coli* and *Legionella pneumophila* [30]. The secondary structures and hypothetical 3D model of AbOmpA and PKF protein are shown in Fig. 1.

B

1 MKSRYLQOGMYAAVFTVAAVQANAAVDFSNL 31
 32 VEQVSPAVVSVNVVKKMTQDELLQQQVPEIL 62
 63 KRFFGNQVILIPQQQGPQEKTAYGSAFFISKD 93
 94 GYLLTNHHVIEENASRISITLNDRREIDATVV 124
 125 GSDERTDVALLKVNNGTNYPALRVGNVDRLRV 155
 156 GEPVLAIGSPFGFDYSASAGIVSAKSRNMSG 186
 187 ETSVPFIQTDVALNPGNSGGPLFNQNQGEVVG 217
 218 VNSRIFSGTGGYMGLSFSIPIDVAMDVAEQL 248
 249 KTKGKVTRSYLGVMMQDIIDRNLA DAYKLPKP 279
 280 EGALITQVSPNSPAQKAGLRAAGDVILKLNGA 310
 311 SVLRTSDLLYALNKVQPNQTVQFEVLRDDKT 341
 342 RNISATLATAPDETPATGNQASASKGPVLGM 372
 373 SIRDLAVPEKNALGIYVQDVRGGLAS 403
 404 LSNIIPGDVIIQVNNTQILNSQDFAKVVSNL 434
 435 PKNTVARVGIIRQGQRAMLGLRIO 458

D





Fig. 1. The secondary structures of AbOmpA (1A) and PKF (1B). Amino acid sequences have shown in ClustalX format and the secondary structure represented by Jnetpred (red ribbons are alpha helix; green ribbons are beta strand). The hypothetical model of AbOmpA protein (1C). The N-terminal domain (beta-barrel domain) folds in outer membrane of bacterium which is connected to C-terminal domain by glycine-proline-rich linker. The C-terminal domain (globular domain) interacts with peptidoglycan. The refined model of secreted serine protease PKF (1D). It seems that PKF can be polymerized and constructs a compartment.

We analyzed two proteins (beta barrel domain of AbOmpA and full length PKF protein) by ConSurf tool. These data showed conservation and protrusion of every amino acid, one by one,

A



Legend:

The conservation scale:



Variable Average Conserved

e - An exposed residue according to the neural-network algorithm.

b - A buried residue according to the neural-network algorithm.

f - A predicted functional residue (highly conserved and exposed).

s - A predicted structural residue (highly conserved and buried).

X - Insufficient data - the calculation for this site was performed on less than 10% of the sequences.

that could be used in evaluation of linear B cell epitopes. The results have been represented in Fig. 2.

B




Fig. 2. Predictions of amino acid conservation and linear B cell epitopes of beta barrel domain of AbOmpA (2A) and full length PKF protein (2B) showed major linear B cell epitopes in beta barrel domain of AbOmpA and full length PKF protein (red rectangles). However, the beta barrel domain of AbOmpA had 3 conserved epitopes while PKF had 4 conserved epitopes.

Based on Ellipro results, the numbers of immunogenic linear and conformational epitopes with high score ($P \geq 0.6$), extracted from beta-barrel of AbOmpA were 6 and 4. Whereas,

PKF had 10 and 4, respectively. The DiscoTope results also matched to Ellipro results (Fig. 3).











A**B****C****D**

Fig. 3. The conformational B cell epitopes of beta-barrel domain of AbOmpA and full length PKF protein by Ellipro and DiscoTope. Data showed that the major epitopes in beta-barrel domain of AbOmpA were located on 4 extracellular loops (see 3A and 3B). Moreover, our analysis showed that the conformational epitopes of PKF have been distributed on all domains of this protein (see 3C and 3D). Ellipro results show the amino acid positions of each epitope in yellow color. DiscoTope results show the conformational epitopes (Red = high score, Blue = low score).

DISCUSSION

A previous investigation has proposed several proteins as novel vaccine candidates against *A. baumannii* where proteomic analysis and MALDI-TOF/TOF of outer membrane proteins from *A. baumannii* have revealed 6 immune-reactive proteins, namely Omp34kDa, OmpA, OprB-like, OprC, OXA-23, and iron regulated outer membrane proteins. Remarkably, these proteins are extensively abundant on the bacterial surface and are involved in virulence, growth and antimicrobial resistance [31]. Moreover, reverse vaccinology and *in vitro* proteomic approaches have identified 42 antigens that could be used as potential vaccine targets against MDR *A. baumannii*. These proteins have been found mostly in secretome and/or outer membrane vesicles (OMV), as extracellular or surface-exposed proteins [32]. Bioinformatics tools are now a standard methodology in vaccine research to discover effective candidate proteins and epitopes which could potentially induce proper immune responses [33]. Moreover, reverse vaccinology has a great potential for identification of novel targets for such purposes. For instance, one study has identified 35 outer membrane or extracellular adhesins, as promising *A. baumannii* vaccine targets. [34].

Among proteins of interest from *A. baumannii*, AbOmpA has recently been shown to be involved in serum resistance. It has been shown that AbOmpA would prevent the killing of the bacterium by the complement system, since it could interact with soluble inhibitors of the alternative complement pathway [35]. AbOmpA attaches to Factor H (inhibitor of alternative complement) and protects *A. baumannii* from MAC activation [35]. Moreover, PKF as a secreted serine protease may hydrolyze the complement factor that gives rise to the serum resistance [5]. However, the serum resistance mechanisms of PBP7/8 and PLD are not clear so far. Comparative *in silico* analyses have shown that both AbOmpA and PKF have satisfied characteristics to be considered as vaccine candidates against *A. baumannii*. These proteins have clear roles in bacterial pathogenesis and are more conserved in comparison with other mentioned proteins. They are also surface exposed or secreted proteins, have many MHC binding sites and contain strong linear and conformational B cell epitopes.

Although the role of PBP-7/8 in Gram-negative bacteria is not totally clear, it is known to be an accessory enzyme involved in modulation of cell morphology and separation of daughter cells, without being essential in normal cell elongation. It may also take part in serum resistance, indirectly [27]. In our study this protein had a promising prospect as vaccine target but its pathogenic roles as virulence factor is not clear. Although experimental studies have confirmed that PLD is an *A. baumannii* virulence factor, this protein is not conserved at all (OMD was 0.101). Moreover, it is localized in cytoplasmic fluid.

The *in silico* analyses of AbOmpA showed this protein forms two independent domain structures; namely, N-terminal and C-terminal domains. The N-terminal forms an 8 strand beta-barrel channel which has 4 loops, exposed to the extracellular spaces. A soluble and stable globular domain in C-terminal of the protein interacts with the peptidoglycan layer in the periplasmic space and it is required for the integrity of the cell [36]. Multiple sequence alignments of beta-barrel domain showed L4 was conserved while L1, L3, and L2 had more amino acid changes [29]. The extracellular loops are functional and dynamic regions of this protein which could be involved in

adherence, invasiveness, biofilm formation, apoptosis, immune stimulation, iron metabolism and serum resistance.

The ConSurf plot and OMD showed AbOmpA protein is totally a conserved protein. The experimental studies have also shown that it has crucial roles in pathogenesis of *A. baumannii*. Linear B cell epitope predictions revealed that these epitopes are located on the extracellular loops (see Fig. 2). Although the ConSurf plot showed N- and C-terminals of PKF protein are variable, the active site of this enzyme was conserved (OMD was 0.076). PKF factor as a secreted protein (MetaLocGramN score was 58.74%) had more linear and conformational B cell epitopes in comparison with beta-barrel domain of AbOmpA. Moreover, epitope prediction results of B and T cells suggest that the extracellular loops of beta-barrel domain had prominent characteristics as immunogenic epitopes which could stimulate both humoral and cellular immunities. It is envisaged that in principle, such extracellular loops could also be used for delivering short immunogenic epitopes of other pathogenic bacteria as vaccine targets, either alone or in fusion forms, to elicit strong responses against *A. baumannii*.

ACKNOWLEDGEMENT

The authors would like to thank the personnel in Department of Bacteriology of Pasteur Institute of Iran for their help. This research was supported by Pasteur Institute of Iran under grant number 911, donated to Farzad Badmasti.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

REFERENCES

1. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *NAT rev microbiol*. 2007;5(12):939-51. doi:10.1038/nrmicro1789.
2. Gordon NC, Wareham DW. Multidrug-resistant *Acinetobacter baumannii*: mechanisms of virulence and resistance. *Int J Antimicrob Agents*. 2010;35(3):219-26. doi:10.1016/j.ijantimicag.2009.10.024.
3. Eliopoulos GM, Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options *Clin Infect Dis*. 2008;46(8):1254-63. doi:10.1086/529198.
4. Mortensen BL, Skaar EP. Host-microbe interactions that shape the pathogenesis of *Acinetobacter baumannii* infection. *Cell Microbiol*. 2012;14(9):1336-44. doi:10.1111/j.1462-5822.2012.01817.x.
5. King LB, Pangburn MK, McDaniel LS. Serine protease PKF of *Acinetobacter baumannii* results in serum resistance and suppression of biofilm formation. *J Infect Dis*. 2013;jis939. doi: 10.1093/infdis/jis939.
6. Jacobs AC, Hood I, Boyd KL, Olson PD, Morrison JM, Carson S et al. Inactivation of phospholipase D diminishes *Acinetobacter baumannii* pathogenesis. *Infection and immunity*. 2010;78(5):1952-62. doi: 10.1128/IAI.00889-09.
7. Russo TA, MacDonald U, Beanan JM, Olson R, MacDonald II, Sauberan SL et al. Penicillin-binding protein 7/8 contributes to the survival of *Acinetobacter baumannii* in vitro and in vivo. *J Infect Dis*. 2009;199(4):513-21. doi: 10.1086/596317.
8. Koenigs A, Stahl J, Averhoff B, Göttig S, Wichelhaus TA, Wallich R et al. CipA of *Acinetobacter baumannii* is a novel plasminogen binding and complement inhibitory protein. *The J Infect Dis*. 2015;213(9):1388-99. doi: 10.1093/infdis/jiv601.
9. Koenigs A, Zipfel PF, Kraiczy P. Translation elongation factor Tuf of *Acinetobacter baumannii* is a plasminogen-binding protein. *PloS one*. 2015;10(7):e0134418. doi: 10.1371/journal.pone.0134418.
10. Liu D, Liu Z-S, Hu P, Cai L, Fu B-Q, Li Y-S et al. Characterization of surface antigen protein 1 (SurA1) from *Acinetobacter baumannii* and its role in virulence and fitness. *Vet Microbiol*. 2016;186:126-38. doi: 10.1016/j.vetmic.2016.02.018.

11. Moxon R, Rappuoli R. Bacterial pathogen genomics and vaccines. *Br Med Bull*. 2002;62(1):45-58. doi.org/10.1093/bmb/62.1.45.

12. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S et al. UniProt: the universal protein knowledgebase. *Nucleic Acids Res*. 2004;32(suppl 1):D115-D9. https://doi.org/10.1093/nar/gkw1099.

13. Magnus M, Pawlowski M, Bujnicki JM. MetaLocGramN: a meta-predictor of protein subcellular localization for Gram-negative bacteria. *Biochim Biophys Acta*. 2012;1824(12):1425-33. doi: 10.1016/j.bbapap.2012.05.018.

14. Marchler-Bauer A, Lu S, Anderson JB, Chitsaz F, Derbyshire MK, DeWeese-Scott C et al. CDD: a Conserved Domain Database for the functional annotation of proteins. *Nucleic Acids Res*. 2011;39(suppl 1):D225-D9. doi: 10.1093/nar/gkq1189.

15. Saha S, Raghava G. VICMpred: an SVM-based method for the prediction of functional proteins of Gram-negative bacteria using amino acid patterns and composition. *GPB*. 2006;4(1):42-7. doi: 10.1016/S1672-0229(06)60015-6.

16. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. *BMC bioinformatics*. 2007;8(1):4. doi.org/10.1186/1471-2105-8-4.

17. He Y, Xiang Z, Mobley HL. Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. *Biomed Res Int*. 2010;2010. doi: 10.1155/2010/297505.

18. Ruffier M, Kähäri A, Komorowska M, Keenan S, Laird M, Longden I et al. Ensembl core software resources: storage and programmatic access for DNA sequence and genome annotation. *Database*. 2017;2017. doi: 10.1093/database/bax020.

19. Glaser F, Pupko T, Paz I, Bell RE, Bechor-Shental D, Martz E et al. ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. *Bioinformatics*. 2003;19(1):163-4. doi: 10.1093/bioinformatics/19.1.163.

20. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. *Molecular biology and evolution*. 2013;30(12):2725-9. DOI: 10.1093/molbev/mst197.

21. Drozdetskiy A, Cole C, Procter J, Barton GJ. JPred4: a protein secondary structure prediction server. *Nucleic acids res*. 2015;43(W1):W389-W94. doi.org/10.1093/nar/gkv332.

22. Wu S, Zhang Y. LOMETS: a local meta-threading-server for protein structure prediction. *Nucleic acids res*. 2007;35(10):3375-82. doi:10.1093/nar/gkm251.

23. Xu D, Zhang Y. Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. *Biophysical J*. 2011;101(10):2525-34. doi: 10.1016/j.bpj.2011.10.024.

24. Ponomarenko J, Bui H-H, Li W, Fusseder N, Bourne PE, Sette A et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. *BMC bioinformatics*. 2008;9(1):514. doi: 10.1186/1471-2105-9-514.

25. Park JS, Lee WC, Yeo KJ, Ryu K-S, Kumarasiri M, Hesek D et al. Mechanism of anchoring of OmpA protein to the cell wall peptidoglycan of the gram-negative bacterial outer membrane. *The FASEB J*. 2012;26(1):219-28. doi: 10.1096/fj.11-188425.

26. Wessler S, Schneider G, Backert S. Bacterial serine protease HtrA as a promising new target for antimicrobial therapy. *Cell Commun Signal*. 2017;15(1):4. doi:10.1186/s12964-017-0162-5.

27. Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. *FEMS Microbiol Rev*. 2008;32(2):234-58. doi: 10.1111/j.1574-6976.2008.00105.x.

28. Selvy PE, Lavieri RR, Lindsley CW, Brown HA. Phospholipase D: enzymology, functionality, and chemical modulation. *Chem. Rev*. 2011;111(10):6064-119. doi: 10.1021/cr200296t.

29. Badmasti F, Siadat S, Bouzari S, Nasiri O, Nemati H, Shahcheraghi F. Molecular analysis of AbOmpA type-1 as immunogenic target for therapeutic interventions against MDR *Acinetobacter baumannii* infection. *Vaccine Res*. 2015;2(3):9-18. doi:10.18869/acadpub.vacres.2.3.9.

30. Krojer T, Sawa J, Schäfer E, Saibil HR, Ehrmann M, Clausen T. Structural basis for the regulated protease and chaperone function of DegP. *Nature*. 2008;453(7197):885-90. doi: 10.1038/nature07004.

31. Fajardo Bonin R, Chapeaurouge A, Perales J, Silva JG, do Nascimento HJ, D'Alincourt Carvalho Assef AP et al. Identification of immunogenic proteins of the bacterium *Acinetobacter baumannii* using a proteomic approach. *Proteomics Clin Appl*. 2014;8(11-12):916-23. doi: 10.1002/pcra.201300133.

32. Moriel DG, Beatson SA, Wurpel DJ, Lipman J, Nimmo GR, Paterson DL et al. Identification of novel vaccine candidates against multidrug-resistant *Acinetobacter baumannii*. *PloS one*. 2013;8(10):e77631. doi: 10.1371/journal.pone.0077631.

33. Tong JC, Tan TW, Ranganathan S. Methods and protocols for prediction of immunogenic epitopes. *Brief Bioinform*. 2006;8(2):96-108. doi: 10.1093/bib/bbl038.

34. Ni Z, Chen Y, Ong E, He Y. Antibiotic resistance determinant-focused *Acinetobacter baumannii* vaccine designed using reverse vaccinology. *Int J Mol Sci*. 2017;18(2):458. doi: 10.3390/ijms18020458.

35. Kim SW, Choi CH, Moon DC, Jin JS, Lee JH, Shin J-H et al. Serum resistance of *Acinetobacter baumannii* through the binding of factor H to outer membrane proteins. *FEMS Microbiol Lett*. 2009;301(2):224-31. doi: 10.1111/j.1574-6968.2009.01820.x.

36. Jin JS, Kwon S-O, Moon DC, Gurung M, Lee JH, Kim SI et al. *Acinetobacter baumannii* secretes cytotoxic outer membrane protein A via outer membrane vesicles. *PLoS One*. 2011;6(2):e17027. doi: 10.1371/journal.pone.0017027.

37. Eijkkelkamp BA, Stroher UH, Hassan KA, Paulsen IT, Brown MH. Comparative analysis of surface-exposed virulence factors of *Acinetobacter baumannii*. *BMC genomics*. 2014;15(1):1020. doi:10.1186/1471-2164-15-1020.